Noul signs MOU with Seegene Brazil to bring AI-powered cervical cancer diagnostics to Latin America

Original from: Korea Biomedical Review

Noul said it has signed a memorandum of understanding (MOU) with Seegene Brazil to introduce its AI-based cervical cancer diagnostic solution, miLab CER, to the Brazilian market.

Under the agreement, the two companies will pursue a non-exclusive distribution partnership for Noul’s product portfolio, centered on miLab CER, across Seegene Brazil’s sales territory. The collaboration aims to accelerate Noul’s market entry and boost the adoption of its AI diagnostic platforms in Latin America.

Noul’s miLab CER is a compact, all-in-one diagnostic platform that automates the entire cervical cytology workflow -- from Pap staining to AI-powered image analysis -- at a fraction of the cost and operational complexity of conventional systems. In a recent clinical performance study, the solution demonstrated a 98 percent sensitivity rate in AI interpretation, underscoring its suitability as a screening tool.

The platform has already gained global recognition, receiving a formal usage recommendation from the 2024 WHO-UNITAID report. Even prior to its full market launch, miLab CER has secured procurement contracts in six Latin American countries and is experiencing rising demand in the Middle East, including Qatar.

“The partnership with Seegene Brazil combines their cytology expertise and well-established distribution channels in Brazil with Noul’s AI-powered diagnostic innovation,” Noul CEO David Lim said. “Following our recent agreement with global medical device manufacturer Nihon Kohden, this MOU is part of our broader strategy to engage with global partners that recognize the value of our AI diagnostic technologies.”

The company expects the MOU to serve as a key inflection point for accelerating its entry into Brazil -- home to the eighth-largest healthcare market globally and the largest in Latin America. Brazil’s in vitro diagnostics (IVD) market was valued at approximately $2 billion in 2023 and is projected to grow at an annual rate of 6.1 percent, reaching around $2.7 billion by 2028.

To prepare for commercial entry, Noul is currently undergoing Brazil’s regulatory review through the Medical Device Single Audit Program (MDSAP) for miLab CER.

The solution is particularly relevant in Brazil, where over 17,000 women are diagnosed with cervical cancer annually. According to Brazil’s National Cancer Institute (INCA), cervical cancer ranks third in incidence and fourth in mortality among female cancers in the country.

Source: Noul signs MOU with Seegene Brazil to bring AI-powered cervical cancer diagnostics to Latin America